Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Study Results Point to Possible Survival Link Between Elderly Age, Chemotherapy
Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
Sacubitril/Valsartan Treatment for HFrEF Results in Removal of Prior Authorization Requirement
Study results demonstrate the multimillion-dollar savings achieved among patients with heart failure with reduced ejection fraction (HFrEF) following treatment initiation with sacubitril and valsartan.
What Factors Are Predictive of Lower ART Adherence Among Hispanic, Latino MSM?
Younger age, poverty, recent drug use, depression, and unmet need for ancillary services were linked to lowered antiretroviral therapy (ART) adherence among HIV-positive Hispanic and Latino men who have sex with men (MSM).
Does Cardiogenic Shock Affect Mortality, Heart Failure Risks Among First-time MI Survivors?
At the 1-year mark, following their first myocardial infarction (MI, or heart attack), heart failure hospitalizations and all-cause mortality were higher among patients who also had cardiogenic shock vs those who did not.
Patients, Health Care Providers Prioritize Heart Failure Education Differently
The results of a recent study out of South Korea show that diet management education appeared more important to health care providers than it did their patients, while both expressed the significance of medication knowledge.
Mortality Higher Among Women With Interval vs Screening-Detected Breast Cancers
Results from a study on Canadian women who did and did not participate in a population-based breast cancer screening program show that interval breast cancers are more aggressive and deadlier than screening-detected cancers.